Search the Newsreel

Cytokinetics (CYTK) Stock Looks Near Fair Value Despite UK MYQORZO Approval

Cytokinetics (CYTK) stock has shown strong returns over five years, but its current valuation suggests it's neither a clear bargain nor obviously overvalued. Despite recent UK approval for MYQORZO, the stock's high price-to-book ratio is not a reliable indicator due to the company's development-heavy …

Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Stoke Therapeutics announced that CEO Ian F. Smith will present at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, at 3:00 p.m. ET. The biotechnology company focuses on RNA medicine to restore protein expression, with its lead investigational medicine, zorevunersen, in …

Has Stoke Therapeutics (STOK) Become A Bargain As Losses Widen And ESOP Shares Hit The Shelf?

Wall Street Zen Downgrades Cytokinetics (NASDAQ:CYTK) to Sell

Wall Street Zen downgraded Cytokinetics (NASDAQ:CYTK) to a "sell" rating from "hold," despite the broader analyst consensus remaining a "Moderate Buy." This downgrade follows the biopharmaceutical company's quarterly results, which saw revenue decline 57.1% year-over-year and substantial losses, although reported revenue and EPS still …

Citizens raises Cytokinetics stock price target on strong launch

Citizens has raised its price target for Cytokinetics (NASDAQ:CYTK) to $110 from $105, maintaining a Market Outperform rating, citing the strong launch of MYQORZO and ongoing pipeline development. The company's stock has surged 131% over the past year, currently trading at $81.37, and its …

Cytokinetics (CYTK) Stock Sees MYQORZO Momentum Collide With Mounting Losses

Cytokinetics (CYTK) saw its shares fall 6% despite early success with its new cardiomyopathy drug, MYQORZO, which generated $25.3 million in net product revenue. The company posted a significant net loss of $198.8 million in Q2 2026, widening from the previous year, as heavy …

Stoke Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:STOK) 2026-08-07

Stoke Therapeutics, Inc. (NASDAQ:STOK) released its Q2 2026 earnings call presentation on August 7, 2026. The company reported an EPS of -$0.93, missing estimates by $0.15, and revenue of $9.33M, which beat expectations by $4.24M despite a 32.51% year-over-year decrease. The presentation provides detailed …

Rentokil Initial plc Stock 12‑Month Price Target Cut to $32.31, Implies 32% Upside

The average 12-month price target for Rentokil Initial plc (RTO) stock has been lowered to $32.31 from $32.50, according to estimates from 18 analysts. This new target suggests a potential upside of approximately 32% from the August 6th closing price. The consensus rating among …

CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong

Cytokinetics, Incorporated CYTK reported a second-quarter 2026 loss of $1.50 per share, narrower than the Zacks Consensus Estimate of a loss of $1.63 per share. In the year-ago quarter, the company reported a loss of $1.12 per share. Loss widened year over year due …

Stoke Therapeutics Inc (STOK) Stock News Today

Rentokil Initial PLC (RTO) Stock News Today

Cytokinetics (NASDAQ:CYTK) Shares Down 6.6% - Here's What Happened

Cytokinetics (NASDAQ:CYTK) shares fell 6.6% despite reporting Q2 2026 revenues and EPS that beat analyst expectations. The stock decline was influenced by a significant year-over-year revenue decrease, widening losses, substantial operating cash outflow, and ongoing insider selling. Despite these concerns, Wall Street analysts maintain …

Cytokinetics, Incorporated Stock 12‑Month Price Target Cut to $107.65, Implies 32% Upside

Cytokinetics, Incorporated's average 12-month stock price target has been slightly cut from $108.47 to $107.65 by 20 analysts, still implying a 32% potential upside from its August 6 closing price. The consensus rating remains a "Buy" across 23 covering analysts, with 21 buys and …

CYTOKINETICS INC Q2 2026: Revenue $28.6M, EPS $(1.50) — 10-Q Summary

CYTOKINETICS INC (CYTK) reported Q2 2026 results with revenue of $28.6 million, primarily driven by the first commercial sales of MYQORZO, which generated $25.3 million. The company posted a net loss of $198.8 million and diluted EPS of $(1.50), both wider than the previous …

Needham & Company LLC Forecasts Strong Price Appreciation for Cytokinetics (NASDAQ:CYTK) Stock

Needham & Company LLC raised its price target for Cytokinetics (NASDAQ:CYTK) from $102 to $112, maintaining a "buy" rating and indicating a potential upside of 41.92%. This positive outlook is supported by a "Moderate Buy" consensus from analysts, with the company also exceeding quarterly …

How Investors May Respond To Cytokinetics (CYTK) UK MYQORZO Approval Amid Wider Quarterly Loss

Cytokinetics (CYTK) recently reported a wider net loss in Q2 2026, with revenue decreasing year-over-year. Despite this, the company's cardiac myosin inhibitor, MYQORZO, received UK marketing authorization, offering a potential catalyst for growth. The article discusses how this approval and early MYQORZO uptake could …

Balefire LLC Reduces Position in Rentokil Initial PLC $RTO

Balefire LLC significantly reduced its stake in Rentokil Initial PLC by 72.5% in the second quarter, selling 64,678 shares and retaining 24,585 shares valued at $703,000. Despite this, analyst sentiment remains a "Moderate Buy" with an average price target of $31.90, contrasting with the …

Tokyo Automatic Machinery 1Q Parent Loss Y90.00M Vs Net Y58.00M

Cytokinetics (CYTK) Releases Q2 2026 Earnings: Revenue Beats but Losses Persist

Cytokinetics Q2 2026 Earnings Call Transcript

Cytokinetics reported strong Q2 2026 earnings, driven by better-than-expected MYQORZO launch momentum, with $25.3 million in net product revenue and increased prescriber adoption. The company also announced positive Phase III trial results for aficamten in non-obstructive HCM, planning a supplemental NDA submission in Q4 …

Cytokinetics (NASDAQ:CYTK) Beats Q2 Estimates on Strong MYQORZO Launch

Cytokinetics (NASDAQ:CYTK) exceeded Q2 2026 estimates, reporting a narrower-than-expected loss and product revenue significantly above forecasts, driven by the successful launch of its cardiac drug MYQORZO. Despite the strong financial performance, the company's shares remained unchanged in after-market trading, suggesting the positive results were …

Barclays Reaffirms Their Buy Rating on Rentokil Initial (RTO)

Barclays analyst James Rose has reaffirmed a Buy rating on Rentokil Initial (RTO) with a price target of £6.30. This positive sentiment is supported by the company's recent strong financial performance, reporting increased quarterly revenue and net profit. Corporate insider sentiment is also positive, …

Earnings Flash (CYTK) Cytokinetics, Incorporated Reports Q2 Revenue $28.6M, vs. FactSet Est of $17.6M

Cytokinetics, Incorporated (CYTK) reported its Q2 revenue at $28.6 million, significantly surpassing FactSet's estimate of $17.6 million. The article also mentions recent insider stock sales and regulatory approvals for its heart disease drugs, MYQORZO (Aficamten) and omecamtiv mecarbil. The company specializes in developing muscle …

Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update

Cytokinetics (Nasdaq: CYTK) reported strong second-quarter 2026 financial results, including $25 million in MYQORZO net product revenue and approximately $1.7 billion in cash, cash equivalents, and investments. The company highlighted significant progress in the commercial launch of MYQORZO for obstructive hypertrophic cardiomyopathy (oHCM), with …

Rentokil Initial PLC (NYSE:RTO) Given Consensus Rating of "Moderate Buy" by Analysts

Rentokil Initial PLC (NYSE:RTO) has received a "Moderate Buy" consensus rating from fourteen analysts, with an average 12-month price target of $31.90. The company's shares opened at $24.72, below its moving averages and near its 12-month low, and it recently declared a dividend of …

FMR LLC discloses 8.5% Stoke Therapeutics (STOK) ownership in Schedule 13G/A

FMR LLC has filed an amended Schedule 13G/A, reporting a passive ownership stake of 8.5% in Stoke Therapeutics (STOK) common stock. This represents 5,313,100 shares, with FMR LLC holding sole voting power over 5,312,516 shares and sole dispositive power over all 5,313,100 shares. Abigail …

Analysts Have Made A Financial Statement On Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Second-Quarter Report

Stoke Therapeutics (NASDAQ:STOK) saw its shares rise 8.3% after its second-quarter report, with revenues of US$9.3m exceeding expectations, though losses also increased. Analysts have since raised revenue estimates for 2026 to US$30.2m but also increased loss per share forecasts to US$3.71, indicating higher costs …

Rentokil Initial Discloses Janus Henderson Stake Cut Below 5% Threshold

Rentokil Initial announced that Janus Henderson Group Ltd reduced its stake in the company below the 5% regulatory threshold to 4.995% of voting rights, down from 5.232%. This move, disclosed on July 30, 2026, and filed with the SEC on August 4, 2026, may …

Analysts Are Bullish on Top Industrial Goods Stocks: RTX (RTX), Rentokil Initial (RTO)

Analysts from Bank of America Securities have issued bullish sentiments for several industrial goods stocks. Ronald Epstein maintained a Buy rating for RTX with a Strong Buy consensus and a 7.9% upside. Tim Ramskill also kept a Buy rating on Rentokil Initial, which holds …

[10-Q] CYTOKINETICS INC Quarterly Earnings Report

Stoke Therapeutics Inc (STOK) Earnings Forecast: Future EPS & Revenue Growth Estimates

Cytokinetics (CYTK) Earnings Date and Reports 2026 $CYTK

Cytokinetics (CYTK) Reports Q2 Loss, Beats Revenue Estimates

Cytokinetics (CYTK) came out with a quarterly loss of $1.5 per share versus the Zacks Consensus Estimate of a loss of $1.63. This compares to a loss of $1.12 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report …

How Cytokinetics Incorporated (CYTK) Affects Rotational Strategy Timing

The article analyzes Cytokinetics Incorporated (CYTK) using AI models, revealing divergent sentiment across various time horizons and suggesting choppy market conditions. It outlines three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to optimize position sizing and manage risk for …

Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

Stoke Therapeutics announced that its CEO, Ian F. Smith, and Chief Patient Officer, Jason Hoitt, will present at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The biotechnology company focuses on RNA medicine to restore protein expression, with its lead investigational …

Stoke Therapeutics (NASDAQ:STOK) Insider Sells $208,391.04 in Stock

Stoke Therapeutics insider Barry Ticho sold 7,176 shares of the company's stock for $208,391.04, reducing his holdings by 26%. This sale was made under a Rule 10b5-1 trading plan. The company recently reported mixed quarterly results, with revenue exceeding estimates but a wider-than-expected loss, …